ReviewCNS drugs2011
Assessing QT interval prolongation and its associated risks with antipsychotics.
Review in CNS drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Electrocardiographic identification of drug effects: QT prolongation, arrhythmias, and clinical monitoring.European journal of clinical pharmacology · 2026Pooled it
- Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance.Schizophrenia bulletin · 2021Pooled it
- The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.Psychopharmacology · 2015Pooled it
- A randomized, double-blind, crossover study of the effect of the fluoroquinolone moxifloxacin on glucose levels and insulin sensitivity in young men and women.Diabetes, obesity & metabolism · 2023Trial
- Use of Corrected QT Cutoffs Derived from Biological Variation to Predict Adverse Events Due to Antipsychotic Drugs: Case Report.Clinical practice and cases in emergency medicine · 2026Article
- Ventricular Arrhythmia and Sudden Death Risk With Concomitant Antipsychotic and SSRI Use.JAMA network open · 2026Article
- Neural network analysis of the contribution of psychotropic prescription sequences to the risk of non-psychiatric adverse events in bipolar and schizophrenia spectrum disorders.Frontiers in digital health · 2025Article
- The Association Between Antidepressant Treatment and Heart Rate Deceleration Capacity in Patients With Mood disorders-A Potential New Predictor of Sudden Cardiac Death.Neuropsychiatric disease and treatment · 2025Article
- Severe mental illness: cardiovascular risk assessment and management.European heart journal · 2024Article
- Article
- Serious adverse drug events associated with psychotropic treatment of bipolar or schizoaffective disorder: a 17-year follow-up on the LiSIE retrospective cohort study.Frontiers in psychiatry · 2024Article
- Drug-Induced Secondary Hypertension by Quetiapine Prescription in an Elderly Patient with Anxiety Disorder.ARYA atherosclerosis · 2022Article
- Phenothiazines and their Evolving Roles in Clinical Practice: A Narrative Review.Health psychology research · 2022Article
- Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- T-wave morphology descriptors in patients with bulimia nervosa.Eating and weight disorders : EWD · 2021Article
- The Prevalence, Risk Factors and Clinical Correlates of QTc Prolongation in Chinese Hospitalized Patients With Chronic Schizophrenia.Frontiers in psychiatry · 2021Article
- Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia.Schizophrenia bulletin · 2020Article
- Cardiovascular Adverse Reactions During Antipsychotic Treatment: Results of AMSP, A Drug Surveillance Program Between 1993 and 2013.The international journal of neuropsychopharmacology · 2020Observational
- A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population.Neuropsychiatric disease and treatment · 2019Review
- Improving Quality of Life in Patients at Risk for Post-Intensive Care Syndrome.Mayo Clinic proceedings. Innovations, quality & outcomes · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several antipsychotics are associated with the ventricular tachycardia torsade de pointes (TdP), which may lead to sudden cardiac death (SCD), because of their inhibition of the cardiac delayed potassium rectifier channel. This inhibition extends the repolarization process of the ventricles of the heart, illustrated as a prolongation of the QT interval on a surface ECG. SCD in individuals receiving antipsychotics has an incidence of approximately 15 cases per 10,000 years of drug exposure but the exact association with TdP remains unknown because the diagnosis of TdP is uncertain. Most patients manifesting antipsychotic-associated TdP and subsequently SCD have well established risk factors for SCD, i.e. older age, female gender, hypokalaemia and cardiovascular disease. QT interval prolongation is the most widely used surrogate marker for assessing the risk of TdP but it is considered somewhat imprecise, partly because QT interval changes are subject to measurement error. In particular, drug-induced T-wave changes (e.g. flattening of the T-wave) may complicate the measurement of the QT interval. Furthermore, the QT interval depends on the heart rate and a corrected QT (QTc) interval is often used to compensate for this. Several correction formulas have been suggested, with Bazett's formula the most widely used. However, Bazett's formula overcorrects at a heart rate above 80 beats per minute and, therefore, Fridericia's formula is considered more appropriate to use in these cases. Several other surrogate markers for TdP have been developed but none of them is clinically implemented yet and QT interval prolongation is still considered the most valid surrogate marker. Although automated QT interval determination may offer some assistance, QT interval determination is best performed by a cardiologist skilled in its measurement. A QT interval >500 ms markedly increases the risk for TdP and SCD, and should lead to discontinuation of the offending drug and, if present, correction of underlying electrolyte disturbances, particularly serum potassium and magnesium derangements. Before prescribing antipsychotics that may increase the QTc interval, the clinician should ask about family and personal history of SCD, presyncope, syncope and cardiac arrhythmias, and recommend cardiology consultation if history is positive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.